Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy

NCT03106987 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03106987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03106987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 8, 2017
Completion date
February 17, 2022
Enrollment
220 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer